DIAN-TU: solanezumab and gantenerumab yield disappointing results for rare form of Alzheimer’s

An initial analysis of the Dominantly Inherited Alzheimer’s Network-Trials Unit (DIAN-TU) has revealed that solanezumab and gantenerumab did not slow memory loss or cognitive decline in people with autosomal dominant Alzheimer’s disease. The Phase II/III international trial indicated that neither drug met the primary outcome of the study (i.e., slowing of cognitive decline as measured by multiple tests of thinking and memory). “Although the drugs we evaluated were not successful, the trial will move us forward in understanding Alzheimer’s,” commented principal investigator, Randall Bateman (Washington University School of Medicine, MO, USA). “The trial’s innovative design – developed in collaboration with...